Ladenburg Thalmann analyst Matthew Kaplan upgraded United Therapeutics to Buy from Neutral and raised his price target for the shares to $106 from $103. The analyst is encouraged by the product sales reported by the company in Q2. He expects United Therapeutics to continue to maintain a "significant" market share in pulmonary hypertension with Remodulin due to practitioner preference. The company will be able to maintain a "relatively steady" revenue base and potentially continue to grow revenues as its pipeline advances to replace their genericized products, Kaplan tells investors in a research note.